Kyverna Files First IND to Leverage CAR-T Therapy for Lupus

Kyverna Therapeutics filed its first IND application this week to test the efficacy and tolerability of KYV-101, a CAR-T therapy for lupus nephritis.

In an interview with BioSpace, Chief Executive Officer Peter Maag, Ph.D., and Chief Medical Officer James Chung, M.D., Ph.D., spoke about the IND filing and the unique characteristics of KYV-101.